Eli Lilly's Mounjaro and Zepbound Sales Boosted in Q1

Demand for Eli Lilly’s blockbuster GLP-1 medicines, Mounjaro and Zepbound, remains strong, generating $6.15 billion in sales in Q1 2025. Sales recovered due to new international launches and improved supply. Lilly’s broader portfolio, including Verzenio and Taltz, also contributes to growth. Analysts estimate Q2 sales for Mounjaro at $4.5 billion and Zepbound at $3.1 billion.

In the obesity market, Eli Lilly competes with Novo Nordisk, dominating with semaglutide medicines. Viking Therapeutics is also making progress with an investigational obesity drug, VK2735. Lilly’s stock has outperformed the industry YTD but is considered expensive. Analysts expect consistent bottom-line estimates for 2025 and a slight decline for 2026.

The semiconductor market is booming as data demand grows. A chipmaker poised for growth specializes in products not offered by industry giants like NVIDIA. Investors can access more information on this stock for free. Novo Nordisk, Eli Lilly, and Viking Therapeutics stock analysis reports are available for further insights.

Read more at Nasdaq: Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?